Opus Genetics Q1 EPS Forecast Decreased by Lifesci Capital

Opus Genetics, Inc. (NASDAQ:IRD) – Equities researchers at Lifesci Capital reduced their Q1 2026 earnings estimates for Opus Genetics in a research report issued on Tuesday, March 10th. Lifesci Capital analyst F. Brisebois now expects that the company will earn ($0.14) per share for the quarter, down from their previous estimate of ($0.13). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. Lifesci Capital also issued estimates for Opus Genetics’ Q2 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.49) EPS.

Several other research firms have also recently commented on IRD. B. Riley Financial initiated coverage on shares of Opus Genetics in a research note on Wednesday, December 10th. They set a “buy” rating and a $9.00 target price on the stock. Craig Hallum set a $9.00 price objective on Opus Genetics and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a report on Thursday, January 22nd. BTIG Research raised their target price on Opus Genetics from $7.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Wall Street Zen raised Opus Genetics from a “sell” rating to a “hold” rating in a report on Sunday, March 1st. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $9.25.

Opus Genetics Stock Up 3.9%

Shares of IRD opened at $5.03 on Friday. The company’s fifty day moving average is $3.19 and its two-hundred day moving average is $2.33. The firm has a market cap of $346.87 million, a PE ratio of -6.13 and a beta of 0.45. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.18. Opus Genetics has a fifty-two week low of $0.65 and a fifty-two week high of $5.30.

Institutional Investors Weigh In On Opus Genetics

Several large investors have recently modified their holdings of IRD. Occudo Quantitative Strategies LP acquired a new stake in Opus Genetics during the 4th quarter worth about $25,000. Virtu Financial LLC acquired a new stake in shares of Opus Genetics during the 4th quarter valued at $34,000. Johnson Investment Counsel Inc. acquired a new stake in Opus Genetics during the fourth quarter valued at $40,000. Raymond James Financial Inc. grew its stake in shares of Opus Genetics by 95.6% in the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after buying an additional 11,000 shares in the last quarter. Finally, Blair William & Co. IL lifted its stake in Opus Genetics by 12.3% in the fourth quarter. Blair William & Co. IL now owns 27,466 shares of the company’s stock valued at $55,000 after acquiring an additional 3,000 shares during the last quarter. 14.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Opus Genetics news, Director Cam Gallagher purchased 83,000 shares of the firm’s stock in a transaction on Monday, December 29th. The shares were purchased at an average price of $1.97 per share, for a total transaction of $163,510.00. Following the completion of the transaction, the director owned 83,000 shares in the company, valued at $163,510. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.60% of the company’s stock.

Trending Headlines about Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Multiple firms raised price targets and reiterated positive ratings (supports upside momentum). Chardan raised its target to $11 with a Buy rating. Chardan price target raise
• Positive Sentiment: Wedbush boosted its target to $10 and kept an Outperform rating—another endorsement from a sell‑side shop. Wedbush price target raise
• Positive Sentiment: BTIG raised its price target to $12 (from $7) and maintained a Buy—adds to the cluster of higher targets that can drive investor interest. BTIG note
• Positive Sentiment: Clinical update: Opus provided progress on its Nyxol (oxymetazoline) clinical program (Phase 3 presbyopia/night‑vision studies), which is a near‑term catalyst investors watch for regulatory/market readthroughs. Clinical trial update
• Neutral Sentiment: H.C. Wainwright publicly remains constructive on Opus (keeps a Buy stance), which supports ongoing investor confidence even amid forecast changes. HC Wainwright buy rating
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates across 2026 quarters and lowered FY2026 (to −$0.64) and FY2027/FY2028 forecasts substantially — this reflects a darker near‑term profitability outlook and could pressure the stock if clinical/operational progress stalls.
• Negative Sentiment: Lifesci Capital also trimmed Q1/Q2 and FY2026 EPS estimates (despite keeping a Strong‑Buy rating), signaling some analyst caution about timing or magnitude of revenue/cost assumptions.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.